Comparisons of variations of Ig, FLC, ACPA, and RF in patients with and without disease remission after 6 months of abatacept therapy. Data are expressed as the median (25th–75th percentile).
| Remission, n = 16 | Not Remission, n = 14 | |||||
|---|---|---|---|---|---|---|
| T0 | T6 | p | T0 | T6 | p | |
| Serum IgA, mg/dl | 322 (248–363) | 242 (182–343) | 0.016 | 463 (360–694) | 353 (269–474) | 0.007 |
| Serum IgM, mg/dl | 175 (149–210) | 163 (112–185) | NS | 189 (108–195) | 127 (74–152) | 0.013 |
| Serum IgG, mg/dl | 1295 (1014–1370) | 1075 (885–1112) | 0.006 | 1340 (1140–1390) | 1070 (929–1230) | 0.009 |
| κ chain, mg/l | 23.0 (16.4–28.9) | 17.3 (13.6–20.3) | 0.019 | 35.5 (19.1–36.1) | 20.3 (14.7–26.2) | NS |
| λ chain, mg/l | 14.7 (12.1–17.0) | 11.7 (10.7–14.5) | 0.016 | 18.9 (15.4–27.8) | 14.1 (12.9–23.1) | NS |
| IgA ACPA, IU/ml | 7.5 (5.2–80.9) | 7.4 (3.1–39.5) | 0.011 | 203.2 (13.3–378.4) | 159.8 (10–268.4) | NS |
| IgG ACPA, IU/ml | 242 (174–425) | 140 (83–273) | 0.022 | 1004.8 (31.4–1884.8) | 606.4 (18–1272) | NS |
| IgA RF, IU/ml | 15.3 (10.4–41.5) | 10.2 (3–23.4) | 0.014 | 35.4 (12.6− > 100) | 23.4 (5−> 100) | NS |
| IgM RF, IU/ml | 101 (34.3–129.4) | 40.5 (4.5–97.7) | 0.008 | 31 (4.3–455) | 4.15 (1.0–289) | NS |
| IgG RF, IU/ml | 7.3 (3.75–10.8) | 3 (2.1–9.9) | NS | 4.2 (1.6–12.8) | 1.5 (0.2–15.4) | NS |
NS: not significant; T0: first administration of ABA; T6: after 6 months of ABA treatment; ACPA: anticitrullinated protein antibodies; RF: rheumatoid factor; FLC: free light chains; Ig: immunoglobulin.